Alpha 2.0
Login Register
» Authors » Eric A Severson

Eric A Severson

Explore the profile of Eric A Severson including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 40
Citations 1304
Followers 0
Related Specialties
Oncology
Cell Biology
Allergy & Immunology
Top 10 Co-Authors
Shakti Ramkissoon
Jeffrey S Ross
Marcia Eisenberg
Charles A Parkos
Shakti H Ramkissoon
Kyle C Strickland
Taylor J Jensen
Mary K Nesline
Heidi Ko
Sarabjot Pabla
Published In
Front Oncol
Cancer Med
JCO Precis Oncol
Oncol Ther
Mol Biol Cell
Affiliations
Soon will be listed here.
Recent Articles
1.
Analytical Validation of the Labcorp Plasma Complete Test, a Cell-Free DNA Comprehensive Genomic Profiling Tool for Precision Oncology
Verner E, Jackson J, Maddox C, Valkenburg K, White J, Occean J, et al.
J Mol Diagn . 2025 Jan; 27(3):216-231. PMID: 39818317
To help guide treatment decisions and trial matching, tumor genomic profiling is an essential precision oncology tool. Liquid biopsy, a complementary approach to tissue testing, can assess tumor-specific DNA alterations...
2.
Genomic profiling of NSCLC tumors with the TruSight oncology 500 assay provides broad coverage of clinically actionable genomic alterations and detection of known and novel associations between genomic alterations, TMB, and PD-L1
Wallen Z, Nesline M, Tierno M, Roos A, Schnettler E, Husain H, et al.
Front Oncol . 2024 Dec; 14:1473327. PMID: 39664186
Introduction: Matching patients to an effective targeted therapy or immunotherapy is a challenge for advanced and metastatic non-small cell lung cancer (NSCLC), especially when relying on assays that test one...
3.
Analysis of real world FRα testing in ovarian, fallopian tube, and primary peritoneal cancers
Previs R, Strickland K, Wallen Z, Ko H, Green M, Cooper M, et al.
Gynecol Oncol . 2024 Dec; 192():102-110. PMID: 39631181
Background: Epithelial ovarian cancer (EOC) remains a significant challenge in gynecologic oncology, particularly in the context of platinum-resistant disease. Mirvetuximab soravtansine (MIRV), was approved after trials revealed favorable response and...
4.
Case report: Single gene testing and comprehensive genomic profiling in non-small cell lung cancer-a case series of divergent results from a large reference laboratory
Strickland K, Nesline M, Previs R, Ko H, Cooper M, Rushton J, et al.
Front Oncol . 2024 Nov; 14:1445668. PMID: 39544293
Clinical management of non-small cell lung cancer (NSCLC) requires accurate identification of tumor-specific genetic alterations to inform treatment options. Historically, providers have relied on single-gene testing (SGT) for actionable variants...
5.
A consensus-based classification workflow to determine genetically inferred ancestry from comprehensive genomic profiling of patients with solid tumors
Wallen Z, Nesline M, Pabla S, Gao S, Vanroey E, Hastings S, et al.
Brief Bioinform . 2024 Oct; 25(6). PMID: 39471413
Disparities in cancer diagnosis, treatment, and outcomes based on self-identified race and ethnicity (SIRE) are well documented, yet these variables have historically been excluded from clinical research. Without SIRE, genetic...
6.
Comprehensive Assessment of Immune Phenotype and Its Effects on Survival Outcomes in HER2-Low versus HER2-Zero Breast Cancer
Ko H, Seager R, Pabla S, Senosain M, Van Roey E, Gao S, et al.
Breast Cancer (Dove Med Press) . 2024 Aug; 16:483-495. PMID: 39192887
Background: The understanding of molecular characteristics of HER2-low breast cancer is evolving since the establishment of trastuzumab deruxtecan. Here, we explore the differences in expression patterns of immune-related genes in...
7.
Real-world comprehensive genomic and immune profiling reveals distinct age- and sex-based genomic and immune landscapes in tumors of patients with non-small cell lung cancer
Wallen Z, Ko H, Nesline M, Hastings S, Strickland K, Previs R, et al.
Front Immunol . 2024 Jul; 15:1413956. PMID: 38975340
Introduction: Younger patients with non-small cell lung cancer (NSCLC) (<50 years) represent a significant patient population with distinct clinicopathological features and enriched targetable genomic alterations compared to older patients. However,...
8.
Immunologic Factors Associated with Differential Response to Neoadjuvant Chemoimmunotherapy in Triple-Negative Breast Cancer
Seager R, Ko H, Pabla S, Senosain M, Kalinski P, Van Roey E, et al.
J Pers Med . 2024 May; 14(5). PMID: 38793063
KEYNOTE-522 resulted in FDA approval of the immune checkpoint inhibitor pembrolizumab in combination with neoadjuvant chemotherapy for patients with early-stage, high-risk, triple-negative breast cancer (TNBC). Unfortunately, pembrolizumab is associated with...
9.
The Impact of Prior Single-Gene Testing on Comprehensive Genomic Profiling Results for Patients with Non-Small Cell Lung Cancer
Nesline M, Subbiah V, Previs R, Strickland K, Ko H, DePietro P, et al.
Oncol Ther . 2024 Mar; 12(2):329-343. PMID: 38502426
Introduction: Tissue-based broad molecular profiling of guideline-recommended biomarkers is advised for the therapeutic management of patients with non-small cell lung cancer (NSCLC). However, practice variation can affect whether all indicated...
10.
Cancer testis antigen burden (CTAB): a novel biomarker of tumor-associated antigens in lung cancer
Seager R, Senosain M, Van Roey E, Gao S, DePietro P, Nesline M, et al.
J Transl Med . 2024 Feb; 22(1):141. PMID: 38326843
Background: Cancer-testis antigens (CTAs) are tumor antigens that are normally expressed in the testes but are aberrantly expressed in several cancers. CTA overexpression drives the metastasis and progression of lung...